ANEBULO PHARMACEUTICALS, INC.: operating expenses
Operating expenses for ANEBULO PHARMACEUTICALS, INC. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All ANEBULO PHARMACEUTICALS, INC. financial histories
What this measure means
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
Exact concept: us-gaap:OperatingExpenses. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2020-07-01 to 2025-06-30. The SEC response was captured on 2026-09-21.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2024-07-01 | 2025-06-30 | 9,223,481 | USD | 2025-09-29 | 10-K · 0001493152-25-016015 |
| 2023-07-01 | 2024-06-30 | 8,308,755 | USD | 2025-09-29 | 10-K · 0001493152-25-016015 |
| 2022-07-01 | 2023-06-30 | 11,783,599 | USD | 2024-09-25 | 10-K · 0001493152-24-038127 |
| 2021-07-01 | 2022-06-30 | 6,831,174 | USD | 2023-09-22 | 10-K · 0001493152-23-033452 |
| 2020-07-01 | 2021-06-30 | 3,613,753 | USD | 2022-09-09 | 10-K · 0001493152-22-025448 |
Related financial histories
- ANEBULO PHARMACEUTICALS, INC.: total assets
- ANEBULO PHARMACEUTICALS, INC.: total liabilities
- ANEBULO PHARMACEUTICALS, INC.: stockholders equity
- ANEBULO PHARMACEUTICALS, INC.: cash and cash equivalents
- ANEBULO PHARMACEUTICALS, INC.: net income or loss
- ANEBULO PHARMACEUTICALS, INC.: operating cash flow
- ANEBULO PHARMACEUTICALS, INC.: financing cash flow
- ANEBULO PHARMACEUTICALS, INC.: retained earnings or deficit
- ANEBULO PHARMACEUTICALS, INC.: basic weighted-average shares
- ANEBULO PHARMACEUTICALS, INC.: diluted weighted-average shares
- ANEBULO PHARMACEUTICALS, INC.: basic earnings per share
- ANEBULO PHARMACEUTICALS, INC.: diluted earnings per share
- ANEBULO PHARMACEUTICALS, INC.: share-based compensation expense
- ANEBULO PHARMACEUTICALS, INC.: operating income or loss
- ANEBULO PHARMACEUTICALS, INC.: current assets
- ANEBULO PHARMACEUTICALS, INC.: interest expense
- ANEBULO PHARMACEUTICALS, INC.: current accounts payable
- ANEBULO PHARMACEUTICALS, INC.: research and development expense
Inspect the source
- Entity
- ANEBULO PHARMACEUTICALS, INC. / CIK 0001815974
- Captured
- 2026-09-21T17:28:29.433Z
- SEC response SHA-256
9b7fbc7aa6627d1ba25b78b2b6216133888564e8abee26c007f1576dedf9e9dd
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001815974.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))